HistoSonics has secured four new positive medical policy decisions from Highmark Blue Cross Blue Shield, expanding insurance coverage for its non-invasive histotripsy treatment for liver tumors. The updated coverage now extends to approximately 7 million members across New York, Delaware, Pennsylvania, and West Virginia.
HistoSonics’ Edison system, an FDA-cleared, image-guided robotic platform, uses focused ultrasound energy to mechanically destroy and liquefy targeted liver tumors without the invasiveness or toxicity of traditional treatments. The company has treated nearly 2,000 patients to date and is also exploring kidney tumor applications.
The expanded Highmark decision builds on initial insurance wins announced in May and is seen as a critical step in establishing broader payer confidence. HistoSonics, which recently shared positive 12-month data on safety and efficacy, is reportedly valued at $2.5 billion and may be a future acquisition target for major medtech players.
Follow MEDWIRE.AI for more breakthroughs in non-invasive oncology treatments.
